MOLINA ARTURO MD

CIK 00013989404 companiesNEWARK, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001398940

Recent Transactions

50 trades

Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-20$82.48/sh−9,514→ 97,266 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-02+32,000→ 32,000 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-02+25,600→ 106,780 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-11-17$84.77/sh−2,712→ 81,180 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-06-10$8.04/sh+10,000→ 93,892 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-06-10$57.03/sh−10,000→ 83,892 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-06-10−10,000→ 75,971 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-06-09−10,000→ 85,971 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-06-09$55.51/sh−10,000→ 83,892 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-06-09$8.04/sh+10,000→ 93,892 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-03-13−28,437→ 69,063 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-03-13−2,077→ 47,785 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-03-13$38.98/sh+2,077→ 114,406 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-03-13$23.42/sh+28,437→ 112,329 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-03-13$55.74/sh−30,514→ 83,892 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-01-16−3,252→ 83,892 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-01-16−388→ 87,144 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-01-02+41,088→ 87,532 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-01-02+49,862→ 49,862 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-27$8.04/sh+10,000→ 56,444 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-27$8.04/sh+16,000→ 62,444 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-27$44.83/sh−16,000→ 46,444 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-11-27−10,000→ 111,971 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-27$44.50/sh−10,000→ 46,444 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-11-27−16,000→ 95,971 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-26$8.04/sh+5,529→ 51,973 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-11-26−5,529→ 121,971 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-26$45.60/sh−5,529→ 46,444 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-15$40.98/sh−1,906→ 46,444 total
Tax Payment
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-01-16$24.63/sh−427→ 48,350 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-01-02+26,250→ 48,777 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-01-02+97,500→ 97,500 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-11-15$16.24/sh−1,848→ 22,527 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2023-01-16+18,750→ 18,750 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-01-16+3,125→ 24,375 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2022-11-15+21,250→ 21,250 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2022-11-15+127,500→ 127,500 total
Disposition to Issuer
Forma Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2022-10-14−16,750→ 0 total
Disposition from Tender
Forma Therapeutics Holdings, Inc.
Common Stock
2022-10-14−10,000→ 0 total
Disposition to Issuer
Forma Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2022-10-14−6,750→ 0 total
Award
Forma Therapeutics Holdings, Inc.
Common Stock
2022-06-08+4,500→ 10,000 total
Award
Forma Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2022-06-08+6,750→ 6,750 total
Tax Payment
SUTRO BIOPHARMA, INC.$STRO
Common Stock
2022-03-05$8.17/sh−4,355→ 37,736 total
Exercise/Conversion
SUTRO BIOPHARMA, INC.$STRO
Restricted Stock Unit (RSU)
2022-03-05−12,500→ 37,500 total
Exercise/Conversion
SUTRO BIOPHARMA, INC.$STRO
Common Stock
2022-03-05+12,500→ 42,091 total
Award
SUTRO BIOPHARMA, INC.$STRO
Restricted Stock Unit (RSU)
2022-03-04+39,000→ 39,000 total
Award
SUTRO BIOPHARMA, INC.$STRO
Stock Option (right to buy Common Stock)
2022-03-04+52,000→ 52,000 total
Exercise/Conversion
SUTRO BIOPHARMA, INC.$STRO
Restricted Stock Unit (RSU)
2022-01-29−5,250→ 10,500 total
Exercise/Conversion
SUTRO BIOPHARMA, INC.$STRO
Common Stock
2022-01-29+5,250→ 31,742 total
Tax Payment
SUTRO BIOPHARMA, INC.$STRO
Common Stock
2022-01-29$10.39/sh−2,151→ 29,591 total

Companies

Recent Filings

Address

C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140

NEWARK, CA, 94560-1160

View on SEC.gov